Daiichi Sankyo - Downside Limited from Here
With Effient (prasugrel, antiplatelet) and Savaysa (edoxaban, anti-coagulant), Daiichi Sankyo looked relatively well prepared to see through the...
193 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
518 Views
Quizartinib: FMS–like Tyrosine Kinase 3 (FLT 3) Inhibitor
Acute Myeloid Leukemia (AML) represents one of the largest hematologic cancer populations with one of the worst survival rates. Patients with r/r...
175 Views
American Society of Hematology- (ASH) Annual Conference (2016) Review
We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...
356 Views
American Society of Hematology (ASH) -Annual Conference (2016) Preview
With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...
220 Views